Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Pattern of lateral neck metastases in N0 papillary thyroid carcinoma

Authors: Vincent Patron, Cécile Bedfert, Guy Le Clech, Karine Aubry, Franck Jegoux

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Indication and extent of lateral prophylactic neck dissection (PLND) in papillary thyroid carcinoma (PTC) is very controversial.

Methods

We retrospectively analysed 131 patients who underwent thyroidectomy and prophylactic lateral neck dissection from level II to V for PTC.

Results

140 PLND were performed. The occult lymph node metastases (OLNM) overall rate was 18.6%. The incidence of node involvement was 10% at level III and 6.4% at level IIa. Level IV and level Vb were both concerned by 5.7% OLNM. Only 2.9% of level IIb contained OLNM. None of the level Va ND revealed OLNM.

Conclusions

OLNM from PTC occurs commonly in level IIa, III, IV and Vb. Incidence in other levels is low. For surgeons that usually perform PLND, we believe that a selective neck dissection of levels IIa, III, IV and Vb in N0 neck PTC is sufficient for the clearance of occult metastases.
Appendix
Available only for authorised users
Literature
1.
Noguchi S, Noguchi A, Murakami N: Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer. 1970, 26: 1053-1060. 10.1002/1097-0142(197011)26:5<1053::AID-CNCR2820260513>3.0.CO;2-X.CrossRefPubMed
2.
Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990, 19: 545-576.PubMed
3.
Attie JN, Khafif RA, Steckler RM: Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg. 1971, 122: 464-471. 10.1016/0002-9610(71)90469-7.CrossRefPubMed
4.
Carcangiu ML, Zampi G, Rosai J: Papillary thyroid carcinoma: a study of its many morphologic expressions and clinical correlates. Pathol Annu. 1985, 20 (Pt 1): 1-44.PubMed
5.
Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB: Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1988, 14: 1063-1075. 10.1016/0360-3016(88)90381-1.CrossRefPubMed
6.
Shaha AR: The National Cancer Data Base Report on thyroid carcinoma: reflections of practice patterns. Cancer. 1998, 83: 2434-2436. 10.1002/(SICI)1097-0142(19981215)83:12<2434::AID-CNCR5>3.0.CO;2-M.CrossRefPubMed
7.
Fukui Y, Yamakawa T, Taniki T, Numoto S, Miki H, Monden Y: Sentinel lymph node biopsy in patients with papillary thyroid carcinoma. Cancer. 2001, 92: 2868-2874. 10.1002/1097-0142(20011201)92:11<2868::AID-CNCR10129>3.0.CO;2-I.CrossRefPubMed
8.
Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, Som P, Wolf GT: Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. 2002, 128: 751-758.CrossRefPubMed
9.
White ML, Doherty GM: Level VI lymph node dissection for papillary thyroid cancer. Minerva Chir. 2007, 62: 383-393.PubMed
10.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009, 19: 1167-1214. 10.1089/thy.2009.0110.CrossRefPubMed
11.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006, 154: 787-803. 10.1530/eje.1.02158.CrossRefPubMed
12.
Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007, 31: 2085-2091. 10.1007/s00268-007-9224-y.CrossRefPubMed
13.
Bardet S, Malville E, Rame JP, Babin E, Samama G, De Raucourt D, Michels JJ, Reznik Y, Henry-Amar M: Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008, 158: 551-560. 10.1530/EJE-07-0603.CrossRefPubMed
14.
Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y: Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003, 237: 399-407. 10.1097/00000658-200303000-00015.PubMedPubMedCentral
15.
Kupferman ME, Patterson M, Mandel SJ, LiVolsi V, Weber RS: Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2004, 130: 857-860. 10.1001/archotol.130.7.857.CrossRefPubMed
16.
Pingpank JF, Sasson AR, Hanlon AL, Friedman CD, Ridge JA: Tumor above the spinal accessory nerve in papillary thyroid cancer that involves lateral neck nodes: a common occurrence. Arch Otolaryngol Head Neck Surg. 2002, 128: 1275-1278.CrossRefPubMed
17.
Ducci M, Appetecchia M, Marzetti M: Neck dissection for surgical treatment of lymphnode metastasis in papillary thyroid carcinoma. J Exp Clin Cancer Res. 1997, 16: 333-335.PubMed
18.
Lee J, Sung TY, Nam KH, Chung WY, Soh EY, Park CS: Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients?. World J Surg. 2008, 32: 716-721. 10.1007/s00268-007-9381-z.CrossRefPubMed
19.
Sivanandan R, Soo KC: Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg. 2001, 88: 1241-1244. 10.1046/j.0007-1323.2001.01843.x.CrossRefPubMed
20.
Mann B, Buhr HJ: Lymph node dissection in patients with differentiated thyroid carcinoma--who benefits?. Langenbecks Arch Surg. 1998, 383: 355-358. 10.1007/s004230050148.CrossRefPubMed
21.
Roh JL, Kim JM, Park CI: Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol. 2008, 15: 1177-1182. 10.1245/s10434-008-9813-5.CrossRefPubMed
22.
Kupferman ME, Weinstock YE, Santillan AA, Mishra A, Roberts D, Clayman GL, Weber RS: Predictors of level V metastasis in well-differentiated thyroid cancer. Head Neck. 2008, 30: 1469-1474. 10.1002/hed.20904.CrossRefPubMed
23.
Cheng PT, Hao SP, Lin YH, Yeh AR: Objective comparison of shoulder dysfunction after three neck dissection techniques. Ann Otol Rhinol Laryngol. 2000, 109: 761-766.CrossRefPubMed
24.
Dijkstra PU, van Wilgen PC, Buijs RP, Brendeke W, de Goede CJ, Kerst A, Koolstra M, Marinus J, Schoppink EM, Stuiver MM, et al: Incidence of shoulder pain after neck dissection: a clinical explorative study for risk factors. Head Neck. 2001, 23: 947-953. 10.1002/hed.1137.CrossRefPubMed
25.
Weiss MH, Harrison LB, Isaacs RS: Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg. 1994, 120: 699-702.CrossRefPubMed
Metadata
Title
Pattern of lateral neck metastases in N0 papillary thyroid carcinoma
Authors
Vincent Patron
Cécile Bedfert
Guy Le Clech
Karine Aubry
Franck Jegoux
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-8

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk

Research article

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

Research article

CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers

Research article

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

Research article

Diet folate, DNA methylation and genetic polymorphisms of MTHFRC677T in association with the prognosis of esophageal squamous cell carcinoma

Research article

Effects of EpCAM overexpression on human breast cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits